Saturday 17 October 2026 Export CRBU’s income statement to Excel — free account

Caribou Biosciences, Inc.

Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.

0.47 0.00 0.00%

Follow CRBU

Alert me

Market cap: $49.8M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 3/9
Altman Z: −5.00
Beneish M: −3.93
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	5	—	—	—	—	—	—	—	—

Insider Ownership 3.39%

Capital & Financial Ratios $m

Market Cap 49.82

Revenue 10.04

Net Income (103.40)

Free Cash Flow (132.79)

Net Debt (112.31)

Current Ratio 6.49

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.55)

P/S ratio 4.73

P/B ratio 0.48

Past 5Y EPS Growth —

This Y EPS Growth 43.90%

Next Y EPS Growth (22.42%)

Next Y revenue growth 114.71%

Next 5Y EPS Growth (2.05%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.60%

10-year low 10-year high

P/B against its own 10 years 8.05%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	329	210	139	112
Receivables	2	2	2	1
Inventory	—	—	—	—
Other	1	1	1	1
	339	219	145	117

	2023	2024	2025	Q'26
Payables	3	2	6	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	28	31	25	18

Compound Annual Growth %

	10y	5y	3y
Sales	—	(2.03%)	(6.95%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	46.86%	(25.95%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	1	—	—	—
’25	2	3	2	4	11
’24	2	3	2	2	10
’23	4	4	24	4	34
’22	3	4	3	4	14
’21	2	1	4	3	10
’20	2	8	1	—	12

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(27)	(23)	—	—	—
’25	(37)	(28)	(25)	(21)	(111)
’24	(37)	(33)	(33)	(35)	(138)
’23	(28)	(15)	(29)	(21)	(93)
’22	(22)	(22)	(22)	(25)	(91)
’21	20	(16)	(15)	(21)	(33)
’20	(9)	(16)	(9)	(8)	(33)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(27)	63	—	—	—
’25	(38)	94	(148)	(21)	(112)
’24	(39)	(35)	(33)	(36)	(143)
’23	(30)	(18)	(34)	(24)	(105)
’22	(22)	(24)	(24)	(27)	(97)
’21	20	(17)	(16)	(22)	(35)
’20	(9)	(17)	(9)	(8)	(34)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	(0.24)	—	—	—
’25	(0.43)	(0.58)	(0.30)	(0.28)	(1.59)
’24	(0.46)	(0.42)	(0.38)	(0.39)	(1.65)
’23	(0.46)	(0.48)	(0.12)	(0.39)	(1.38)
’22	(0.32)	(0.44)	(0.44)	(0.44)	(1.64)
’21	(1.39)	(1.39)	(0.46)	(0.31)	(2.11)
’20	(0.16)	(0.22)	(0.93)	—	(4.01)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	14.17	4.89	3.44	1.50	0.66	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	32.65	15.85	8.59	8.33	3.54
People
People	Employees	—	—	—	—	—	97	137	158	147	97
	Revenue/emp, $m	—	—	—	0.00	0.00	0.10	0.10	0.22	0.07	0.12
Income, $m
Income, $m	Revenue	—	—	—	6	12	10	14	34	10	11
	Gross margin, %	—	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	—	(31)	(36)	(67)	(99)	(102)	(149)	(149)
	EBT margin, %	—	—	—	(535.04)	(292.27)	(693.92)	(717.28)	(295.49)	(1,492.04)	(1,332.33)
	Net income	—	0	—	(23)	(34)	(67)	(99)	(102)	(149)	(148)
	Depreciation	—	—	—	1	1	1	1	(1)	(1)	3
Per share, $
Per share, $	Revenue	—	—	—	0.69	1.45	0.30	0.23	0.47	0.11	0.12
	Earnings	—	—	—	(2.80)	(4.01)	(2.11)	(1.64)	(1.38)	(1.65)	(1.59)
	Cash flow	—	—	—	(3.82)	(3.89)	(1.03)	(1.50)	(1.26)	(1.53)	(1.19)
	Capex	—	—	—	(0.11)	(0.04)	(0.07)	(0.11)	(0.16)	(0.05)	(0.01)
	Free cash flow	—	—	—	(3.93)	(3.92)	(1.09)	(1.60)	(1.42)	(1.58)	(1.20)
	Book value	—	—	—	0.00	2.09	12.25	4.95	4.99	2.80	1.31
	Shares, m	—	—	—	8	9	32	61	74	90	93
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	13.15	13.15	49.78	29.02	11.92	14.37	13.31
	P/B	—	—	—	0.00	0.00	1.23	1.34	1.12	0.57	1.22
	EV/Sales	—	—	—	2.98	2.98	10.62	11.14	2.39	(6.60)	0.82
	EV/FCF	—	—	—	(2.82)	(2.82)	(2.94)	(1.58)	(0.78)	0.46	(0.08)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(32)	(33)	(33)	(91)	(93)	(138)	(111)
	Capex	—	—	—	(1)	0	(2)	(6)	(12)	(5)	(1)
	Free cash flow	—	—	—	(33)	(34)	(35)	(97)	(105)	(143)	(112)
Balance, $m
Balance, $m	Working capital	—	—	—	47	12	365	232	311	189	120
	Total debt	—	—	—	42	43	0	28	—	—	—
	Net debt	—	—	—	(41)	(16)	(376)	(248)	(329)	(210)	(139)
	Shareholders’ equity	—	—	—	—	18	388	301	368	253	122
Returns, %
Returns, %	ROA	—	—	—	0.00	(190.36)	(27.98)	(24.36)	(25.33)	(40.00)	(60.62)
	ROIC	—	—	—	0.00	(1,168.00)	(349.05)	(124.98)	(183.29)	(239.87)	0.00
	ROE	—	—	—	293.36	429.55	(36.73)	(28.87)	(30.50)	(47.99)	(78.97)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INKT MiNK Therapeutics, Inc.	$50.7M	— (loss-making)	—	—	n/m	−32.73% (below 0%: shrinking)	0.00%	0.00%	Compare
LONA LeonaBio, Inc.	$49.8M	— (loss-making)	—	—	n/m	−142.29% (below 0%: shrinking)	0.00%	0.00%	Compare
CRBU Caribou Biosciences, Inc.	$49.8M	— (loss-making)	— (loss-making)	−43.79% (below 0%: shrinking)	n/m	−33.16% (below 0%: shrinking)	100.00%	(1,690.39%)
MREO Mereo BioPharma Group plc - Sponsored ADR	$49.3M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
HYPD Hyperion DeFi, Inc.	$49.0M	— (loss-making)	3.6×	+2,333.33% (above 0%: growing)	n/m	+86.82% (above 0%: growing)	100.00%	8,668.63%	Compare
HOWL Werewolf Therapeutics, Inc.	$48.5M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
ELTX Elicio Therapeutics, Inc.	$48.2M	— (loss-making)	— (loss-making)	−55.27% (below 0%: shrinking)	n/m	+8.77% (above 0%: growing)	0.00%	0.00%	Compare
ACET Adicet Bio, Inc.	$48.1M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$48.7M	—	—	+491.92%	—	+16.47%	0.00%	0.00%

All 614 Biotechnology stocks →

Caribou Biosciences, Inc. (CRBU) key facts

Strength: Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024.
Caribou Biosciences, Inc. (CRBU) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRBU traded at $0.47, a market capitalization of $49.8 million.
Return on equity was −79.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.00 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.